Skip to content
Confidence in biological medicines
Stay connected
Shopping Basket
Pay Now
Login / Register
Home
Products
Standardisation
Control testing
Science and research
Expert services
About us
QE2
Menu
Products
Standardisation
Control testing
Science and research
Expert services
About us
QE2
Advanced therapies
Virology
Bacteriology
Biotherapeutics
Analytical sciences
Infectious Disease Diagnostics
A to Z listing
Publications
Sub Menu
Home
/
Science and research
/
Virology
/
Establishment of the first WHO International Standard for anti-Rift Valley fever virus antibodies
Establishment of the first WHO International Standard for anti-Rift Valley fever virus antibodies
The NIBSC, in collaboration with the Coalition for Epidemic Preparedness
Innovations (CEPI) and partners Integrum Scientific (USA) in partnership with the Uganda Virus Research Institute (UVRI) and Technical University of
Mombasa (Kenya), is currently developing the first WHO International Standard for
anti-Rift Valley fever virus antibodies. (
https://cepi.net/news_cepi/efforts-to-advancerift-valley-fever-vaccines-progress-with-new-cepi-partnership/
)
The antibody standard is a pool of serum or plasma from multiple patients who have
recovered from Rift valley fever. The intended use is to calibrate available kits and
assays for the detection of antibodies specific for Rift valley fever virus; this allows
comparability between the results from different laboratories, epidemiology studies,
vaccine clinical trials.
We are recruiting laboratories to assess and to support the establishment of this
antibody standard.
To join our collaborative study, please email our Project Lead,
Giada.mattiuzzo@nibsc.org
Your browser does not support JavaScript!
Your browser does not support JavaScript!